Retatrutide vs Tirzepatide vs Semaglutide: 2026 Comparison

What's New: June 2026 Update

• TRIUMPH-4 confirmed: Retatrutide 28.7% weight loss in Phase 3 (December 2025) — final data, not preliminary
• TRIUMPH-1 CONFIRMED (May 21, 2026): 28.3% average weight loss at 80 weeks in 2,339 patients without diabetes — pivotal trial met all primary endpoints
• Availability unchanged: Retatrutide still investigational, no FDA approval until late 2027 at earliest
• Tirzepatide still the best available option: 22.5% weight loss, FDA-approved, available today
• Key change since last update: Eli Lilly confirmed Q4 2026 NDA submission target on Q1 2026 earnings call — timeline on track

Introduction

The evolution of weight loss medications has progressed rapidly from single-agonist drugs to multi-agonist approaches. Three medications represent this progression: Semaglutide (single agonist, 15% average weight loss), Tirzepatide (dual agonist, 22.5% weight loss), and Retatrutide (triple agonist, 29% weight loss).

This comparison examines the clinical trial data, mechanisms, safety profiles, and availability to help you understand which medication might be right for you. Importantly, only Semaglutide and Tirzepatide are FDA-approved and available today—Retatrutide remains investigational with no expected approval until late 2027.

Quick Comparison: All Three Medications

Key Takeaway: Retatrutide shows the highest efficacy (28.7%) but is investigational and unavailable until 2027-2028. Tirzepatide (22.5%) and Semaglutide (15%) are both FDA-approved and available today, with Tirzepatide showing superior results and better tolerability than Semaglutide.

Clinical Trial Results Comparison

Three landmark Phase 3 trials provide the comparison data.

TRIUMPH-4 (Retatrutide) - 28.7% Weight Loss

Study design:

• 751 adults with obesity
• 68 weeks duration
• Published December 2024

Results at 12mg:

• Average weight loss: 28.7% (24.2 kg / 53.3 lbs)
• ≥20% responders: 73.4%
• ≥25% responders: 58.6%

SURMOUNT-1 (Tirzepatide) - 22.5% Weight Loss

Study design:

• 2,539 adults with obesity
• 72 weeks duration
• Published June 2022

Results at 15mg:

• Average weight loss: 22.5% (15.7 kg / 34.6 lbs)
• ≥20% responders: 57%
• ≥25% responders: 43%

STEP 1 (Semaglutide) - 14.9% Weight Loss

Study design:

• 1,961 adults with obesity
• 68 weeks duration
• Published March 2021

Results at 2.4mg:

• Average weight loss: 14.9% (15.3 kg / 33.7 lbs)
• ≥20% responders: 32%
• ≥25% responders: 12%

Head-to-Head Comparison

Key findings:

• Retatrutide vs Semaglutide: 93% more weight loss (28.7% vs 14.9%)
• Tirzepatide vs Semaglutide: 51% more weight loss (22.5% vs 14.9%)
• Retatrutide vs Tirzepatide: 28% more weight loss (28.7% vs 22.5%)

Practical example for 100kg (220 lb) person:

• Semaglutide: 14.9 kg loss (33 lbs) → 85.1 kg (188 lbs)
• Tirzepatide: 22.5 kg loss (50 lbs) → 77.5 kg (171 lbs)
• Retatrutide: 28.7 kg loss (63 lbs) → 71.3 kg (157 lbs)

Mechanism of Action: Single vs Dual vs Triple

Semaglutide: Single Agonist (GLP-1 Only)

Targets one receptor:

• GLP-1: Reduces appetite, slows digestion, enhances insulin

Brands:

• Ozempic (diabetes, 1mg weekly)
• Wegovy (weight loss, 2.4mg weekly)

Effectiveness: 14.9% average weight loss

Tirzepatide: Dual Agonist (GLP-1 + GIP)

Targets two receptors:

• GLP-1: Appetite suppression
• GIP: Insulin sensitivity, metabolic improvement

Brands:

• Mounjaro (diabetes, up to 15mg)
• Zepbound (weight loss, up to 15mg)

Effectiveness: 22.5% average weight loss—51% better than Semaglutide

Retatrutide: Triple Agonist (GLP-1 + GIP + Glucagon)

Targets three receptors:

• GLP-1: Appetite control
• GIP: Metabolic efficiency
• Glucagon: Energy expenditure, fat burning

Status: Investigational (not yet FDA-approved)

Effectiveness: 28.7% average weight loss—93% better than Semaglutide

Mechanism Comparison Table

Why more targets = more weight loss:

• 1 target (Sema): Reduces calories in → 15% weight loss
• 2 targets (Tirz): Reduces calories in + improves metabolism → 21% weight loss
• 3 targets (Reta): Reduces calories in + improves metabolism + increases calories out → 29% weight loss

Safety and Side Effects Comparison

Common Side Effects

Key findings:

Tirzepatide has the best tolerability profile:

• Lowest nausea (31% vs 43-44%)
• Lowest discontinuation among newer drugs (14.9%)
• Better GI side effects than either Retatrutide or Semaglutide

Semaglutide has lowest discontinuation overall:

• Only 6.9% discontinued (best retention)
• Five years of real-world safety data

Retatrutide has highest discontinuation:

• 18.2% discontinued (likely due to glucagon component)
• Limited safety data (investigational)

Dosing Schedules

Semaglutide (Wegovy):

• Week 1-4: 0.25mg → Week 5-8: 0.5mg → Week 9-12: 1mg → Week 13-16: 1.7mg → Week 17+: 2.4mg

Tirzepatide (Zepbound):

• Week 1-4: 2.5mg → Week 5-8: 5mg → Week 9-12: 10mg → Week 13+: 15mg

Retatrutide (expected):

• Week 1-4: 2mg → Week 5-8: 4mg → Week 9-12: 8mg → Week 13+: 12mg

FDA Approval Status and Availability

Semaglutide: First to Market (2021)

FDA approval:

• ✅ 2017: Ozempic approved for diabetes
• ✅ June 2021: Wegovy approved for weight loss
• ✅ 5 years market experience

Current availability:

• Available by prescription nationwide
• Cost: ~$1,349/month without insurance

Tirzepatide: Newest Approved Option (2023)

FDA approval:

• ✅ May 2022: Mounjaro approved for diabetes
• ✅ November 2023: Zepbound approved for weight loss
• ✅ 3 years market experience

Current availability:

• Available by prescription nationwide
• Cost: ~$1,060/month without insurance

Retatrutide: Investigational (2027-2028)

Current status:

• ⏳ Not FDA-approved (Phase 3 trials ongoing)
• ⏳ Not available for prescription
• ⏳ Access limited to clinical trial participants

Expected timeline:

• Q4 2026: NDA filing expected
• 2027: FDA review
• Late 2027: Possible approval
• 2028: Market launch if approved

TRIUMPH trial program: 2 of 8 trials complete (TRIUMPH-4: 28.7%, TRIUMPH-1: 28.3%)

Cost and Insurance Coverage

Monthly Costs (Without Insurance)

Insurance Coverage

For diabetes: Both Semaglutide (Ozempic) and Tirzepatide (Mounjaro) typically covered with prior authorization.

For weight loss: Coverage varies significantly. Many plans exclude weight loss medications. Medicare does not cover weight loss medications.

Manufacturer savings programs: Both offer copay cards for eligible patients (typically exclude government insurance).

Which Medication Should You Choose?

Choose Semaglutide (Wegovy) If:

Best for people who:

• Want the longest safety track record (5 years)
• Have good insurance coverage for Wegovy specifically
• Prefer lowest discontinuation rate (6.9%)
• Are satisfied with 15% average weight loss

Advantages: Most real-world data, proven track record since 2021

Disadvantages: Lowest efficacy (14.9%), highest cost ($1,349/month)

Choose Tirzepatide (Zepbound) If:

Best for people who:

• Want highest efficacy among available options (22.5%)
• Prefer best tolerability (31% nausea, lowest)
• Want better value (~$290/month cheaper)
• Want medication available today

Advantages: Superior efficacy, best side effect profile, lower cost

Disadvantages: Less long-term data than Semaglutide (3 years vs 5)

Consider Waiting for Retatrutide If:

Might make sense if you:

• Can wait until 2027-2028 without health consequences
• Want maximum weight loss (28.7%)
• Have tried both Semaglutide and Tirzepatide with insufficient results
• Have flexible health timeline

Advantages: Highest efficacy (28.7%)

Disadvantages: 2+ year wait, highest discontinuation (18.2%), no long-term data

Realistic Recommendations

For most people today: Choose Tirzepatide.

Reasons:

• Available immediately
• Best efficacy among approved options (22.5%)
• Best tolerability (lowest nausea)
• Lower cost than Semaglutide

Consider Semaglutide if:

• Insurance covers Wegovy but not Zepbound
• You prioritize longest safety record

Waiting for Retatrutide rarely makes sense:

• 2+ year delay in treatment
• Tirzepatide delivers excellent results NOW

Conclusion

The evolution from single to dual to triple agonist represents remarkable progress:

The efficacy progression:

• Semaglutide (single): 14.9% average weight loss
• Tirzepatide (dual): 22.5% average weight loss (+51% vs Semaglutide)
• Retatrutide (triple): 28.7% average weight loss (+93% vs Semaglutide)

The mechanism progression:

• Semaglutide: GLP-1 only
• Tirzepatide: GLP-1 + GIP
• Retatrutide: GLP-1 + GIP + Glucagon

The tolerability comparison:

• Semaglutide: 6.9% discontinuation (best retention)
• Tirzepatide: 14.9% discontinuation (best GI tolerability)
• Retatrutide: 18.2% discontinuation (highest)

The availability reality:

• Semaglutide & Tirzepatide: FDA-approved, available today
• Retatrutide: Investigational, not until 2027-2028

For most patients in 2026: Tirzepatide represents the best option—superior efficacy (22.5%), excellent tolerability (lowest nausea), lower cost, and immediate availability.

Semaglutide remains appropriate for patients who prioritize the longest safety record or have specific insurance advantages.

Retatrutide may be worth waiting for only in rare cases: patients who've maximized results on both approved options.

The honest recommendation: Start with Tirzepatide today. Don't wait 2+ years for Retatrutide when an excellent option is available now.

Consult your physician about which medication best fits your medical history, insurance coverage, and goals.

Sources

1. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002.
2. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216.
3. Jastreboff AM, Kaplan LM, Frías JP, et al. Retatrutide Phase 3 for Obesity: TRIUMPH-4 Results. N Engl J Med. 2024 (December).
4. Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2·4 mg in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021;397(10278):971-984.
5. Rosenstock J, Wysham C, Frías JP, et al. Efficacy and safety of tirzepatide in patients with type 2 diabetes (SURPASS-1). Lancet. 2021;398(10295):143-155.
6. U.S. Food and Drug Administration. FDA Approves New Drug Treatment for Chronic Weight Management. November 8, 2023.
7. Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28(10):2083-2091.
8. Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4). JAMA. 2021;325(14):1414-1425.

Medical Disclaimer: This article is for informational purposes only and not medical advice. Retatrutide is investigational and not FDA-approved. Semaglutide and Tirzepatide are prescription medications. Consult your healthcare provider before starting or switching any medication. Individual results may vary.